Erasca (ERAS) Income towards Parent Company (2020 - 2026)
Erasca (ERAS) posted Income towards Parent Company of -$860.7 million for Q1 2026, down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025, and down 2218.06% year-over-year from $40.6 million in Q1 2025.
Erasca (ERAS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Erasca's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$860.7 million for Q1 2026.
- Quarterly Income towards Parent Company fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
- Income towards Parent Company was -$860.7 million for Q1 2026 at Erasca, down from -$34.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$34.1 million in Q4 2025 and bottomed at -$860.7 million in Q1 2026.
- A 5-year average of -$118.7 million and a median of -$55.7 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company soared 74.06% — and 2026, when it sank 2218.06%.
- Erasca's Income towards Parent Company stood at -$139.1 million in 2022, then surged by 74.06% to -$36.1 million in 2023, then decreased by 3.71% to -$37.4 million in 2024, then grew by 8.84% to -$34.1 million in 2025, then sank by 2423.74% to -$860.7 million in 2026.
- Business Quant data shows ERAS's Income towards Parent Company at -$860.7 million in Q1 2026, -$34.1 million in Q4 2025, and -$51.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Erasca | 5.83 Bn | 5.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -860.70 Mn |
| Dec 31, 2025 | -34.10 Mn |
| Sep 30, 2025 | -51.08 Mn |
| Jun 30, 2025 | -55.74 Mn |
| Mar 31, 2025 | -37.13 Mn |
| Dec 31, 2024 | -37.41 Mn |
| Sep 30, 2024 | -53.90 Mn |
| Jun 30, 2024 | -143.98 Mn |
| Mar 31, 2024 | -46.38 Mn |
| Dec 31, 2023 | -36.07 Mn |
| Sep 30, 2023 | -60.57 Mn |
| Jun 30, 2023 | -120.78 Mn |
| Mar 31, 2023 | -45.78 Mn |
| Dec 31, 2022 | -139.07 Mn |
| Sep 30, 2022 | -124.98 Mn |
| Jun 30, 2022 | -66.60 Mn |
| Mar 31, 2022 | -103.70 Mn |
| Dec 31, 2021 | -31.35 Mn |
| Sep 30, 2021 | -288.26 Mn |
| Jun 30, 2021 | -110.92 Mn |